Cyclacel Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
David Lazar
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 14.6yrs |
Recent management updates
Recent updates
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely
Aug 17
Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis
Aug 07Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?
Apr 15Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video)
Oct 04Cyclacel issues key business objectives for 2021
Jan 11Cyclacel Pharma inks securities purchase agreement for $7M
Dec 22Cyclacel Pharmaceuticals EPS misses by $1.74
Nov 11CEO
David Lazar
no data
Tenure
Mr. David Lazar is Interim CEO of Cyclacel Pharmaceuticals, Inc. from January 2025.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | 18.8yrs | US$661.05k | 0.10% $ 2.3k | |
| Executive VP of Finance | 18.8yrs | US$352.62k | 0.030% $ 672.9 | |
| Independent Chair of the Board | 10.3yrs | US$97.99k | 0.0010% $ 23.3 | |
| Director | no data | no data | no data |
14.6yrs
Average Tenure
68yo
Average Age
Experienced Board: CYCC's board of directors are seasoned and experienced ( 14.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 00:11 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cyclacel Pharmaceuticals, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | H.C. Wainwright & Co. |
| Kimberly Lee | Janney Montgomery Scott LLC |
| Michael King | JMP Securities |